SEDIABETES - www.avancesendiabetologia.org
Buscador avanzado
Ver artículo
Av. Diabetol. 2009;25(3):205-208

Disminuir tamaño de letra Aumentar tamaño de letra Imprimir texto

Quality of life outcomes in subjects with type 1 diabetes with and without repeated hypoglycaemia. Short-term results of CSII treatment

Artículos originales - Vol.25 N.3  mayo-junio 2009
M. Giménez Álvarez1, M. Lara2, M. Jansà3, M. Vidal4, I. Levy5, I. Conget Donlo6

 Filiaciones de autores


Resumen

Objectives: To evaluate quality of life (QoL) characteristics and outcomes in subjects with T1D with and without non-severe (NSH)/severe hypoglycaemia (SH) as a main indication for CSII. Patients and methods: Two groups of T1D subjects were selected from candidates to CSII following the criteria of the Catalan National Health Service. Twenty-one subjects (aged 34.6±7.5 years; 13 women) in whom CSII was started because of recurrent NSH and SH) were included (H Group). They were compared to 18 T1D subjects (aged 32.3±10.1 years; 14 women) in whom CSII was initiated because of non-optimal control without repeated NSH/SH (NH group). General characteristics, metabolic control and QoL/health state (DQoL/ SF-12 questionnaires) were evaluated (baseline/after 12-months). Results: In the H group, the number of NSH/week diminished from 5.01±1.56 (baseline) to 2.76±1.09 after 12 months (p <0.001). SH diminished from 1.24±0.62 per subject year (baseline) to 0.12±0.21 (12 months, p <0.001). There were no differences in A1c (6.9±1.3 vs 6.5±0.8%; NH and H) after 12-months of CSII. The H group scored better in DQoL-impact of treatment subscale at baseline (45.7±7.0 vs 33.7±7.3; p <0.001, NH and H). QoL improved similarly after 12 months in both groups, but the difference in DQoL-impact of treatment (41.5±8.5 vs 31.0±5.8; p <0.001) was maintained. Conclusions: CSII improves QoL independently of its main indication. Subjects who initiate CSII because of repeated hypoglycaemic episodes display a different QoL perception than those without this indication when starting this therapy. Although this finding does not preclude favorable results, probably it has to be considered in order to encourage patients to start this modality of treatment.

Correspondencia

Correspondencia: I. Conget. Endocrinology and Diabetes Unit. IDIBAPS (Institut d’Investigacions
Biomèdiques August Pi i Sunyer). CIBER de Diabetes y Enfermedades
Metabólicas asociadas (CIBERDEM). Villarroel, 170. 08036 Barcelona (Spain).
E-mail: iconget@clinic.ub.es

Palabras clave

calidad de vida diabetes mellitus tipo 1 ISCI repeated hypoglycaemia

Documento

Documento PDF»

‹ Volver